Long term physical sequelae after adult-onset cancer

Journal of Cancer Survivorship

Volumn 2, Issue 1, 2008, Pages 3-11

  Fosså, Sophie D ^a,b   Vassilopoulou Sellin, Rena ^c   Dahl, Alv A ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adult onset; Guidelines; Long term effects; Patient care plan; Transitional research

Indexed keywords

ADULT; AGED; ARTICLE; CLASSIFICATION; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; NEOPLASM; NORWAY; ONSET AGE; POSTOPERATIVE COMPLICATION; PSYCHOLOGICAL ASPECT; SECOND CANCER; STATISTICS; SURVIVOR; TIME; UNITED STATES;

ADULT; AGE OF ONSET; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; NORWAY; POSTOPERATIVE COMPLICATIONS; SURVIVORS; TIME FACTORS; UNITED STATES;

EID: 40849094416     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-007-0039-5     Document Type: Article

References (101)

1. Office of Cancer Survivorship. Estimated US cancer prevalence counts: who are our cancer survivors in the US? 2005 Bethesda, MD: National Cancer Institute. http://cancercontrol.cancer.gov/ocs/prevalence.
2. Cancer Registry of Sweden. http://www.socialstyrelsen.se.
3. Cancer Registry of Denmark. http://www.sst.dk.
4. Cancer Registry of Finland. http://www.cancerregistry.fi.
5. Cancer Registry of Norway. http://www.kreftregisteret.no.
6. Institute of Medicine and National Research Council. Cancer survivors in: from cancer patient to cancer survivor. In: Hewett M, Greenfield S, Stovall E, editors. Lost in transition. Washington DC: The National Academic Press; 2005. pp. 23-65.
7. Skinner R, Wallace WHB, Levitt GA, on behalf of the UK Children's Cancer Study Group (UKCCSG), Late Effects Group (LEG). Long-term follow-up of people who have survived cancer during childhood. Lancet Oncol 2006;7:489-98.
8. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355(15):1572-82.
9. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Health profiles in 5836 long-term cancer survivors. Int J Cancer 2003;104(4):488-95.
10. Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci 2003;58(1):82-91.
11. Nord C, Mykletun A, Thorsen L, Bjøro T, Fosså SD. Self-reported health and use of health care services in long-term cancer survivors. Int J Cancer 2005;114(2):307-16.
12. Rao AV, Denmark-Wahnefried W. The older cancer survivor. Crit Rev Oncol/Hematol 2006;60(2):131-43.
13. Deimling GT, Kahana B, Bowman KF, Schaefer ML. Cancer survivorship and psychological distress in later life. Psychooncology 2002;11(6):479-94.
14. Garman KS, Pieper CF, Seo P, Cohen HJ. Function in elderly cancer survivors depends on comorbidities. J Gerontol A Biol Sci Med Sci 2003;58(12):1119-24.
15. Rowland JH, Yancik R. Cancer survivorship: the interface of aging, comorbidity, and quality care. J Nat Cancer Inst 2006;98(8):504-5.
16. Ganz PA. Why and how to study the fate of cancer survivors: observations from the clinic and the research laboratory. Eur J Cancer 2003;39(15):2136-41.
17. Aziz NA, Rowland JH. Trends and advances in cancer survivorship research: challenge and opportunities. Semin Radiat Oncol 2003;13:248-66.
18. Ayanian JZ, Jacobsen PB. Enhancing research on cancer survivors. J Clin Oncol 2006;24(32):5149-53.
19. Tichelli A and Socié G. Considerations for adult cancer survivors. Hematology Am Soc Hematol Educ Program 2005;516-22.
20. Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, Hall P, Langmark F, Pukkala E, Andersson M, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007;25(12):1489-97.
21. Dong C, Hemminki K. Second primary neoplasms in 633,964 cancer patients in Sweden, 1958-1996. Int J Cancer 2001;93(2):155-61.
22. Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomark Prev 2006;15(11):2020-6.
23. Oosterhuis JW, Looijenga LHJ. Current views on the pathogenesis of testicular germ cell tumours and perspectives for future research: highlights of the 5th Copenhagen workshop on carcinoma in situ and cancer of the testis. APMIS 2003;111(1):280-9.
24. Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 2006;4(2):156-76.
25. Ghelani D, Saliba R, de Lima M. Secondary malignancies after hematopoietic stem cell transplantation. Crit Rev Oncol/Hematol 2005;56(1):115-26.
26. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005;5(12):943-55.
27. Lillington DM, Micallef IN, Carpenter E, Neat MJ, Amess JA, Matthews J, Foot NJ, Lister TA, Young BD, Rohatiner AZ. Genetic susceptibility to Hodgkin's disease and secondary neoplasias: FISH analysis reveals patients at high risk of developing secondary neoplasia. Ann Oncol 2002;13(Suppl 1):40-3.
28. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97(18):1354-65.
29. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290(4):465-75.
30. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL, et al. Effects of Tamoxifen vs Raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 2006;295(23):2727-41.
31. Prosnitz RG, Chen YH, Marks LB. Cardiac toxicity following thoracic radiation. Semin Oncol 2005;32(2):71-80.
32. Hooning MJ, Botma A, Aleman BMP, Baaijens MH, Bartelink H, Klijn JG, Taylor CW, van Leeuwen FE. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007;99(5):365-75.
33. Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 2003;4(9):529-36.
34. Friedman DL, Constine LS. Late effects of treatment for Hodgkin lymphoma. J Natl Compr Canc Netw 2006;4(3):249-57.
35. Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, van't Veer MB, Baaijens MH, de Boer JP, Hart AA, Klokman WJ, Kuenen MA, Ouwens GM, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109(5):1878-86.
36. Van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodriqus PT, Schimmel EC, Aleman BM, van Leeuwen FE. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006;24(3):467-75.
37. Dewar JA. Postmastectomy Radiotherapy. Clin Oncol 2006;18(3):185-90.
38. Fosså SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, Storm H, Hall P, Holowaty E, Andersen A, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007;99(7):533-44.
39. Wouters KA, Kremer LCM, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of most promising strategies. Br J Haematol 2005;131(5):561-78.
40. Ewer MS, Martin FJ, Henderson IC, Shapiro CL, Benjamin RS, Gabizon AA. Cardiac safety of liposomal anthracyclines. Semin Oncol 2004;31(6):161-81.
41. Nuver J, Smit AJ, Postma A, Sleijfer DT, Gietema JA. The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures. Cancer Treat Rev 2002;28(4):195-214.
42. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21(8):1513-23.
43. Sagstuen H, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Wilsgaard T, Bremnes RM. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005;23(22):4980-90.
44. Fosså SD, Aass N, Winderen M, Börmer OP, Olsen DR. Long-term renal function after treatment for malignant germ cell tumours. Ann Oncol 2003;13(2):222-8.
45. Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 2006;106(4):751-8.
46. Pheilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000;18(7):1570-93.
47. Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004;92(4):287-95.
48. Iversen P, Johansson JE, Lodding P, Kylmala T, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Armstrong T, et al. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand J Urol Nephrol 2006;40(6):441-52.
49. Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AL, Schlichting E, Lien EA, Ofjord ES, Paolini J, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23(22):5126-37.
50. Jonat W. Overview of luteinizing hormone-releasing hormone agonists in early breast cancer-benefits of reversible ovarian ablation. Breast Cancer Res Treat 2002;75:23-6.
51. Fridmans A, Chertin B, Koulikov D, Lindenberg T, Gelver H, Leiter C, Farkas A, Spitz IM. Reversibility of androgen deprivation therapy in patients with prostate cancer. J Urol 2005;173(3):784-9.
52. Howell SJ, Shalet SM. Effect of cancer therapy on pituitary-testicular axis. Int J Androl 2002;25(5):269-76.
53. Haugnes HS, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Wilsgaard T, Bremnes RM. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007;18(2):241-8.
54. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006;24(24):3979-83.
55. Lobo RA. Potential options for preservation of fertility in women. N Engl J Med 2005;353(1):64-73.
56. Haukvik UK, Dieset I, Bjoro T, Holte H, Fossa SD. Treatment-related premature ovarian failure as a long-term complication after Hodgkin's lymphoma. Ann Oncol 2006;17(9):1428-33.
57. Magelssen H, Brydoy M, Fossa SD. The effects of cancer and cancer treatments on male reproductive function. Nat Clin Pract Urol 2006;3(6):312-22.
58. Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005;62(3):738-44.
59. Fosså SD, Magelssen H, Melve K, Jacobsen AB, Langmark F, Skjaerven R. Parenthood in survivors after adulthood cancer and perinatal health in their offspring: a preliminary report. J Natl Cancer Inst Monographs 2005;34:77-82.
60. Brydoy M, Fossa SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Dahl O. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005;97(21):1580-8.
61. Kiserud CE, Fosså A, Holte H, Fosså SD. Post-treatment parenthood Hodgkin's lymphoma survivors. Br J Cancer 2007;96(9):1442-9.
62. Kumar N, Allen KA, Riccardi D, Bercu BB, Cantor A, Minton S, Balducci L, Jacobsen PB. Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit? Breast Cancer Res Treat 2004;83(2):149-59.
63. Agha A, Sherlock M, Brennan S, O'Connor SA, O'Sullivan E, Rogers B, Faul C, Rawluk D, Tormey W, Thompson CJ. Hypothalamic-Pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. J Clin Endocrinol Metab 2005;90(12):6355-60.
64. Tal R, Baniel J. Sexual function-preserving cystectomy. Urology 2005;66(2):235-41.
65. Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta" ). Urology 2005;66(5):83-94.
66. Potosky AL, Davis WW, Hoffman RM, Standford JL, Stephenson RA, Penson DF, Harlan LC. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate cancer Outcome Study. J Natl Cancer Inst 2004;96(18):1358-67.
67. Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol 2002;41(4):427-33.
68. Armstrong CL, Gyato K, Awadalla AW, Lustiq R, Tochner ZA. A critical review of the clinical effects of therapeutic irradiation damage to the brain: the roots of controversy. Neuropsychol Rev 2004;14(1):65-86.
69. Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose Methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS Lymphoma. J Clin Oncol 2006;24(28):4570-4.
70. Galecki J, Hicer-Grzenkowicz J, Grudzien-Kowalska M, Michalska T, Zalucki W. Radiation-induced brachial plexopathy and hypofractionated regimens in adjuvant irradiation of patients with breast cancer - a review. Acta Oncol 2006;45(3):280-4.
71. Mykletun A, Dahl AA, Haaland CF, Bremnes R, Dahl O, Klepp O, Wist E, Fosså SD. Side-effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol 2005;23(13):3061-8.
72. Oldenburg J, Kraggerud Sm, Cvancarova M, Lothe RA, Fosså SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 2007;25(6):708-14.
73. Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004;22(11):2233-9.
74. Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, Ryu JK, Bosch W, Emami B. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005;61(2):318-28.
75. Stensvold E, Aass N, Gladhaug I, Stenwig AE, Claussen OP, Fossa SD. Erroneous diagnosis of pancreatic cancer after radiotherapy of testicular cancer. Eur J Surg Oncol 2004;30(3):352-5.
76. Maduro JH, Pras E, Willemse PHB, de Vries EGE. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev 2003;29:471-88.
77. Green J, Kirwan J, Tierney J, Vale C, Symonds P, Fresco L, Williams C, Collingwood M. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005;20 (3):Review.
78. Lundby L, Krogh K, Jensen VJ, Gandrup P, Qvist N, Overgaard J, Laurberg S. Long-term anorectal dysfunction after postoperative radiotherapy for rectal cancer. Dis Colon Rectum 2005;45(7):1343-9.
79. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8(6):475-87.
80. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ. ASCO Cancer Survivorship Expert Panel. J Clin Oncol 2007;25(25):3991-4008.
81. Working party of the British Committee for Standards in hematology, clinical hematology task force. Guidelines for prevention and treatment of infection in post splenectomy patients or those with dysfunction spleen. Br Med J 1996;312(7028):430-4.
82. Webb CW, Crowell K, Cravens D. Clinical inquiries. Which vaccinations are indicated after splenectomy? J Fam Pract 2006;55(8):711-2.
83. Winquist EW, Bauman GS, Balogh J. Nontraumatic osteonecrosis after chemotherapy for testicular cancer: a systematic review. Am J Clin Oncol 2001;24(6):603-6.
84. Sciubba JJ, Goldenberg D. Oral complications of radiotherapy. Lancet Oncol 2006;7(2):75-83.
85. Gordon KG, Char DH, Sagerman RH. Late effects of radiation on the eye and ocular adnexa. Int J Radiat Oncol Biol Phys 1995;31(5):1123-39.
86. Stava C, Beck M, Vassilopoulou-Sellin R. Cataracts among cancer survivors. Am J Clin Oncol 2005;28(6):603-8.
87. Ness KK, Wall MM, Oakes JM, Robinson LL, Gurney JG. Physical performance limitations and participation restrictions among cancer survivors: a population-based study. Ann Epidemiol 2006;16(3):197-205.
88. Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci 2003;58(1):82-91.
89. Sweeney C, Schmitz KH, Lazovich D, Virnig BA, Wallace RB, Folsom AR. Functional limitations in elderly female cancer survivors. J Natl Cancer Inst 2006;98(8):521-9.
90. Fosså SD, Hess SL, Dahl AA, Hjermstad MJ, Veenstra M. Stability of health-related quality of life in the Norwegian general population and impact of chronic morbidity in individuals with and without a cancer diagnosis. Acta Oncol 2007;46(4):452-61.
91. Ruffer JU, Fletchner H, Tralls P, Josting A, Sieber M, Lathan B, Diehl V. Fatigue in long-term survivors of Hodgkin's lymphoma: a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 2003;39(15):2179-86.
92. Hjermstad MJ, Oldervoll L, Fossa SD, Holte H, Jacobsen AB, Loge JH. Quality of life in long-term Hodgkin's disease survivors with chronic fatigue. Eur J Cancer42(3):327-33.
93. Ng AK, Recklitis C, Neuberg D, Chakrabarti S, Silver B, Diller LA. Comparison between long-term survivors of Hodgkin's disease and their siblings on fatigue level and factors predicting for increased fatigue. Ann Oncol 2005;16(12):1949-55.
94. Kato K, Sullivan PF, Evengård B, Pedersen NL. Premorbid predictors of chronic fatigue. Arch Gen Psychiatry 2006;63(11):1267-72.
95. Bower JE, Ganz PA, Aziz N, Olmstead R, Irwin MR, Cole SW. Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav Immun 2007;21(3):251-8.
96. Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ, American Society of Clinical Oncology. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 2006;24(1):190-205.
97. Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol 2006;24(32):5117-24.
98. Earle CC. Failing to plan is planning to fail: improving the quality of care with survivorship care plans. J Clin Oncol 2006;24(32):5112-6.
99. Demark-Wahnefried W, Pinto BM, Gritz ER. Promoting health and physical function among cancer survivors: potential for prevention and questions that remain. J Clin Oncol 2006;24(32):5125-31.
100. van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MWJ, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BMP, van Leeuwen FE. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007;25(28):4370-8.
101. Ralleigh G, Given-Wilson R. Breast cancer risk and possible screening strategies for young women following supradiaphragmatic irradiation for Hodgkin's disease. Clin Radiol 2004;59(8):647-50.